(Q38833243)

PubMed publication ID

28417463

6 September 2017

title

Pharmacological interventions for primary sclerosing cholangitis: an attempted network meta-analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6464655&resulttype=core&format=json

13 May 2020

main subject

ascending cholangitis

0 references

sclerosing cholangitis

1 reference

primary sclerosing cholangitis

inferred from title

1 reference

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6464655&resulttype=core&format=json

13 May 2020

Francesca Saffioti

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6464655&resulttype=core&format=json

13 May 2020

Kurinchi Selvan Gurusamy

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6464655&resulttype=core&format=json

13 May 2020

Clare D Toon

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6464655&resulttype=core&format=json

13 May 2020

author name string

Neil Hawkins

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6464655&resulttype=core&format=json

13 May 2020

Brian R Davidson

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6464655&resulttype=core&format=json

13 May 2020

Douglas Thorburn

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6464655&resulttype=core&format=json

13 May 2020

publication date

28 March 2017

1 reference

PubMed publication ID

28417463

Cochrane Database of Systematic Reviews

6 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6464655&resulttype=core&format=json

13 May 2020

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6464655&resulttype=core&format=json

13 May 2020

page(s)

CD011343

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6464655&resulttype=core&format=json

High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective

13 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Colchicine treatment of primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis: throwing the urso out with the bathwater?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Efficacy of bezafibrate in a patient with primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Use of mycophenolate mofetil in the treatment of primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Mycophenolate mofetil for the treatment of primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [ISRCTN88246634]

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Efficacy of lidocaine in the treatment of pruritus in patients with chronic cholestatic liver diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

No beneficial effects of transdermal nicotine in patients with primary sclerosing cholangitis: results of a randomized double-blind placebo-controlled cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Graphical tools for network meta-analysis in STATA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

SPIRIT 2013 statement: defining standard protocol items for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Diagnosis and management of primary sclerosing cholangitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Efficacy of new generation antidepressants: differences seem illusory

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Methods for combining randomized clinical trials: strengths and limitations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

EASL Clinical Practice Guidelines: management of cholestatic liver diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

A pilot study of etanercept in the treatment of primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Glucocorticosteroids for primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Liver transplantation for perihilar cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Ischemic cholangiopathy after controlled donation after cardiac death liver transplantation: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

D-penicillamine for primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Outcome stagnation of liver transplantation for primary sclerosing cholangitis in the Model for End-Stage Liver Disease era

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Role of endoscopy in primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Industry sponsorship and research outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

A comparison of methods to detect publication bias in meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

How to use an article reporting a multiple treatment comparison meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Intention-to-treat analysis: implications for quantitative and qualitative research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Role of methotrexate in the treatment of chronic cholestatic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Etiopathogenesis of primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Primary sclerosing cholangitis: role of extrahepatic biliary resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Bile-acid-induced cell injury and protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Bile acids for primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Iatrogenic biliary injuries: identification, classification, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Ursodeoxycholic acid in primary sclerosing cholangitis: if withdrawal is bad, then administration is good (right?).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Natural history and prognostic models in primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Mycophenolate mofetil for the treatment of primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Sample size and power considerations in network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Management of perihilar cholangiocarcinoma in the era of multimodal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Automating network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Diagnosis and classification of primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011343.PUB2

Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group

21 January 2018

1 reference

12 December 2020

A controlled trial of calcitonin therapy for the prevention of post-liver transplantation atraumatic fractures in patients with primary biliary cirrhosis and primary sclerosing cholangitis

1 reference

12 December 2020

Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial

1 reference

12 December 2020

New treatment for primary sclerosing cholangitis: promising results with ursodiol

1 reference

12 December 2020

Therapeutic benefit of sulfasalazine for patients with primary sclerosing cholangitis

1 reference

12 December 2020

[Primary sclerosing cholangitis. To slow progression and reduce carcinoma risk]

1 reference

12 December 2020

Primary sclerosing cholangitis: Is medical therapy on the way?

1 reference

12 December 2020

Sertraline as a first-line treatment for cholestatic pruritus

1 reference

12 December 2020

A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis

1 reference

12 December 2020

Etiopathogenesis of primary sclerosing cholangitis

1 reference

12 December 2020

Ursodeoxycholic acid in primary sclerosing cholangitis

1 reference

12 December 2020

Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study

1 reference

12 December 2020

Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis

1 reference

12 December 2020

[Treatment of primary sclerosing cholangitis with ursodeoxycholic acid]

1 reference

12 December 2020

A Triple Blinded, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis: a Pilot Study

1 reference

12 December 2020

Rifampin as antipruritic agent in primary sclerosing cholangitis

1 reference

12 December 2020

Prospective trial of penicillamine in primary sclerosing cholangitis

1 reference

12 December 2020

Biliary lavage with corticosteroids in primary sclerosing cholangitis. A clinical, cholangiographic and bacteriological study

1 reference

12 December 2020

Abnormalities in tests of copper metabolism in primary sclerosing cholangitis.

1 reference

12 December 2020

Azathioprine treatment in primary sclerosing cholangitis

1 reference

12 December 2020

Ursodeoxycholic acid therapy in treatment of primary sclerosing cholangitis.

1 reference

12 December 2020

Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period

1 reference

12 December 2020

A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis

1 reference

12 December 2020

Promises, promises: ursodeoxycholic acid for primary sclerosing cholangitis

1 reference

12 December 2020

Ursodeoxycholic acid in the treatment of primary sclerosing cholangitis

1 reference

12 December 2020

Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period.

1 reference

12 December 2020

Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response

1 reference

12 December 2020

Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group

1 reference

12 December 2020

[Primary sclerosing cholangitis. Ursodeoxycholic acid is without clinical effect]

1 reference

12 December 2020

[Treatment of primary sclerosing cholangitis: drug, endoscopic, combined or no treatment at all?]

1 reference

12 December 2020

Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses

1 reference

12 December 2020

10.1002/14651858.CD011343.PUB2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6464655&resulttype=core&format=json

13 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6464655&resulttype=core&format=json

13 May 2020

PubMed publication ID

28417463

1 reference